The increased expression of the ASCT2 glutamine transporter and GSL1 have been associated with an increased AR, MYC, and mechanistic “mammalian” target of rapamycin (mTOR) pathways’ activation, to ensure PCa progression, since glutamine is an mTOR effector. The gene discussed is SLC1A5; the disease is posterior cortical atrophy.